The report lists SRF under 'Long Build Up' in derivatives market monitor.
Read this note →SRF Limited
NSE SRF BSE 503806 INE647A01010
0 filings · 0 analysed
2,459.70
-2.37%
over 1 month
-
Equity Morning Report 23rd Oct 2026
The report lists SRF under 'Long Build Up' in derivatives market monitor.
-
HSIE Results Daily 23 Oct 26 HSIE
The report maintains ADD on SRF citing market share protection, pharma scale-up, fluoropolymer growth and PFB value addition, though it notes Q2 EBITDA/APAT were 8/14% below estimates due to raw material cost pressure.
-
Morning Coffee 22 Oct 26 09 05 57 Morning Coffee
The technical snapshot lists SRF as a bearish intraday call with support at 2250 and resistance at 2319.
-
The report notes SRF's 2QFY27 revenue of ₹49.0 billion rose ~35% YoY but EBITDA missed estimates due to a 150bp YoY margin contraction to 20.6%.
-
SBI Securities Daily Derivative Report 22 10 2026
The report notes SRF saw short buildup with price down 5.62% and OI up 6.10%.
-
Chemicals Q2FY27 Results Preview HSIE
The report expects revenue to grow 37.7% YoY but EBITDA margin to contract 406.3bps QoQ to 20.5%.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 23 Oct 2026, 06:27 | long | 2,310.00 | 3,000.00 | 2,460.40 | 22% | open by 2027-10-23 |
| HDFC Securities | 14 Oct 2026, 15:45 | long | 2,499.70 | 3,172.00 | 2,460.40 | -6% | open by 2027-10-14 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report maintains ADD on SRF citing market share protection, pharma scale-up, fluoropolymer growth and PFB value addition, though it notes Q2 EBITDA/APAT were 8/14% below estimates due to raw material cost pressure.
Read this note →The technical snapshot lists SRF as a bearish intraday call with support at 2250 and resistance at 2319.
Read this note →The report notes SRF's 2QFY27 revenue of ₹49.0 billion rose ~35% YoY but EBITDA missed estimates due to a 150bp YoY margin contraction to 20.6%.
Read this note →The report notes SRF saw short buildup with price down 5.62% and OI up 6.10%.
Read this note →The report expects revenue to grow 37.7% YoY but EBITDA margin to contract 406.3bps QoQ to 20.5%.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief